Malignant disease & immunosuppression

Western Devon Health Community Shared Care Guidelines - Malignant disease & immunosuppression

With the merger of the CCGs from 1 April 2019, current shared care guidelines can now be found on the NHS Devon CCG website here.

Hydroxycarbamide for the management of myeloproliferative disorders is no longer covered by shared care arrangements in the Western Locality. This guideline has been removed. For further advice please refer to the South and West Devon Joint Formulary.

Archived guidelines

A number of shared care guidelines have been archived, and are available for reference only.

CCGs are not the responsible commissioners for these treatments; these services fall within the specialised services commissioned by NHS England.  Guidance should be provided to GPs by specialist services if requests are made to share care. 

Rate this page